| Ytd | -55.81% | |
| 1y | -29.44% |
| Open | 0.57 | Prev Close | 0.56 | Low | 0.55 | High | 0.58 | Mkt Cap | 19.05M |
| Vol | 333.48K | Avg Vol | 736.27K | EPS | -1.35 | P/E | N/A | Forward P/E | -3.75 |
| Beta | 0.29 | Short Ratio | 0.32 | Inst. Own | 2.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-16 | 50-d Avg | 0.50 | 200-d Avg | 0.74 | 1yr Est | 2.00 |
KTTA News
Gainers Picard Medical (AMEX:PMI) stock rose 40.2% to $4.5 during Friday's after-market session
Oncobiologics (NASDAQ: OTLK - Get Free Report) and Pasithea Therapeutics (NASDAQ: KTTA - Get Free Re
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK In
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK In
KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 20
MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or t
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-
-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, wit
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Bu
-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and lo
-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and l
-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease
Pasithea Therapeutics (KTTA) appears to have found support after losing some value lately, as indica
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-
MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or t
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145326
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.12) per share which beat the an
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or th
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Bu
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-
MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or
Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) is projected to announce its results before t
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conf
Pasithea Therapeutics (Nasdaq: KTTA) will present to Oppenheimer 36th Annual Healthcare Life Science
Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):Pasithea has completed
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or t
HC Wainwright & Co. analyst Sara Nik initiates coverage on Pasithea Therapeutics (NASDAQ:KTTA
MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (
Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Inv
-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research
-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Coh
